Safety And Efficacy Of Lenalidomide In Patients With Relapsed Or Refractory Aggressive Non-Hodgkin's Lymphoma (NHL)

NCT00179660 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

50

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Hodgkins Lymphoma

Interventions

DRUG: Lenalidomide

Sponsor

Celgene Corporation

Collaborators

[object Object]